These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 30514883)

  • 1. Does relapse contribute to treatment resistance? Antipsychotic response in first- vs. second-episode schizophrenia.
    Takeuchi H; Siu C; Remington G; Fervaha G; Zipursky RB; Foussias G; Agid O
    Neuropsychopharmacology; 2019 May; 44(6):1036-1042. PubMed ID: 30514883
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder.
    Robinson D; Woerner MG; Alvir JM; Bilder R; Goldman R; Geisler S; Koreen A; Sheitman B; Chakos M; Mayerhoff D; Lieberman JA
    Arch Gen Psychiatry; 1999 Mar; 56(3):241-7. PubMed ID: 10078501
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical outcome after antipsychotic treatment discontinuation in functionally recovered first-episode nonaffective psychosis individuals: a 3-year naturalistic follow-up study.
    Mayoral-van Son J; de la Foz VO; Martinez-Garcia O; Moreno T; Parrilla-Escobar M; Valdizan EM; Crespo-Facorro B
    J Clin Psychiatry; 2016 Apr; 77(4):492-500. PubMed ID: 26759992
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
    Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
    Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Olanzapine versus haloperidol treatment in first-episode psychosis.
    Sanger TM; Lieberman JA; Tohen M; Grundy S; Beasley C; Tollefson GD
    Am J Psychiatry; 1999 Jan; 156(1):79-87. PubMed ID: 9892301
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Symptom Remission and Brain Cortical Networks at First Clinical Presentation of Psychosis: The OPTiMiSE Study.
    Dazzan P; Lawrence AJ; Reinders AATS; Egerton A; van Haren NEM; Merritt K; Barker GJ; Perez-Iglesias R; Sendt KV; Demjaha A; Nam KW; Sommer IE; Pantelis C; Wolfgang Fleischhacker W; van Rossum IW; Galderisi S; Mucci A; Drake R; Lewis S; Weiser M; Martinez Diaz-Caneja CM; Janssen J; Diaz-Marsa M; Rodríguez-Jimenez R; Arango C; Baandrup L; Broberg B; Rostrup E; Ebdrup BH; Glenthøj B; Kahn RS; McGuire P;
    Schizophr Bull; 2021 Mar; 47(2):444-455. PubMed ID: 33057670
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Five-fold increased risk of relapse following breaks in antipsychotic treatment of first episode psychosis.
    Winton-Brown TT; Elanjithara T; Power P; Coentre R; Blanco-Polaina P; McGuire P
    Schizophr Res; 2017 Jan; 179():50-56. PubMed ID: 27745754
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beyond Clinical Remission in First Episode Psychosis: Thoughts on Antipsychotic Maintenance vs. Guided Discontinuation in the Functional Recovery Era.
    Alvarez-Jimenez M; O'Donoghue B; Thompson A; Gleeson JF; Bendall S; Gonzalez-Blanch C; Killackey E; Wunderink L; McGorry PD
    CNS Drugs; 2016 May; 30(5):357-68. PubMed ID: 27106296
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and demographic predictors of continuing remission or relapse following discontinuation of antipsychotic medication after a first episode of psychosis. A systematic review.
    Bowtell M; Ratheesh A; McGorry P; Killackey E; O'Donoghue B
    Schizophr Res; 2018 Jul; 197():9-18. PubMed ID: 29146020
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trajectories after first-episode psychosis: Complement to ambiguous outcomes of long-term antipsychotic treatment by exploring a few hidden cases.
    Liu CC; Lin YT; Liu CM; Hsieh MH; Chien YL; Hwang TJ; Hwu HG
    Early Interv Psychiatry; 2019 Aug; 13(4):895-901. PubMed ID: 29927087
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early use of clozapine for poorly responding first-episode psychosis.
    Agid O; Remington G; Kapur S; Arenovich T; Zipursky RB
    J Clin Psychopharmacol; 2007 Aug; 27(4):369-73. PubMed ID: 17632221
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Guided discontinuation versus maintenance treatment in remitted first-episode psychosis: relapse rates and functional outcome.
    Wunderink L; Nienhuis FJ; Sytema S; Slooff CJ; Knegtering R; Wiersma D
    J Clin Psychiatry; 2007 May; 68(5):654-61. PubMed ID: 17503973
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors of Treatment-Resistant and Clozapine-Resistant Schizophrenia: A 12-Year Follow-up Study of First-Episode Schizophrenia-Spectrum Disorders.
    Chan SKW; Chan HYV; Honer WG; Bastiampillai T; Suen YN; Yeung WS; Lam M; Lee WK; Ng RMK; Hui CLM; Chang WC; Lee EHM; Chen EYH
    Schizophr Bull; 2021 Mar; 47(2):485-494. PubMed ID: 33043960
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Rationale for the use of long-acting injectable risperidone: a survey of French psychiatrists].
    Misdrahi D; Delgado A; Bouju S; Comet D; Chiariny JF
    Encephale; 2013 May; 39 Suppl 1():S8-14. PubMed ID: 23541914
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term effects of discontinuation from antipsychotic maintenance following first-episode schizophrenia and related disorders: a 10 year follow-up of a randomised, double-blind trial.
    Hui CLM; Honer WG; Lee EHM; Chang WC; Chan SKW; Chen ESM; Pang EPF; Lui SSY; Chung DWS; Yeung WS; Ng RMK; Lo WTL; Jones PB; Sham P; Chen EYH
    Lancet Psychiatry; 2018 May; 5(5):432-442. PubMed ID: 29551618
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antipsychotic medication versus psychological intervention versus a combination of both in adolescents with first-episode psychosis (MAPS): a multicentre, three-arm, randomised controlled pilot and feasibility study.
    Morrison AP; Pyle M; Maughan D; Johns L; Freeman D; Broome MR; Husain N; Fowler D; Hudson J; MacLennan G; Norrie J; Shiers D; Hollis C; James A;
    Lancet Psychiatry; 2020 Sep; 7(9):788-800. PubMed ID: 32649925
    [TBL] [Abstract][Full Text] [Related]  

  • 17. You say "schizophrenia" and I say "psychosis": Just tell me when I can come off this medication.
    Zipursky RB; Odejayi G; Agid O; Remington G
    Schizophr Res; 2020 Nov; 225():39-46. PubMed ID: 32115315
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A potential role for adjunctive omega-3 polyunsaturated fatty acids for depression and anxiety symptoms in recent onset psychosis: Results from a 16 week randomized placebo-controlled trial for participants concurrently treated with risperidone.
    Robinson DG; Gallego JA; John M; Hanna LA; Zhang JP; Birnbaum ML; Greenberg J; Naraine M; Peters BD; McNamara RK; Malhotra AK; Szeszko PR
    Schizophr Res; 2019 Feb; 204():295-303. PubMed ID: 30241990
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic stability and long-term symptomatic and functional outcomes in first-episode antipsychotic-naïve patients with schizophrenia.
    Klærke LR; Baandrup L; Fagerlund B; Ebdrup BH; Pantelis C; Glenthøj BY; Nielsen MØ
    Eur Psychiatry; 2019 Oct; 62():130-137. PubMed ID: 31614250
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of treatment response in second-episode versus first-episode schizophrenia.
    Emsley R; Oosthuizen P; Koen L; Niehaus D; Martinez L
    J Clin Psychopharmacol; 2013 Feb; 33(1):80-3. PubMed ID: 23277247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.